O Yano
Overview
Explore the profile of O Yano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki T, Fukazawa N, Sato W, Yano O, Tsuruo T
J Med Chem
. 1997 Jun;
40(13):2047-52.
PMID: 9207946
The effect of 24 newly synthesized quinoline derivatives on tumor cell multidrug resistance (MDR) was examined in vitro. At low concentrations, these compounds enhanced the accumulation of [3H]vincristine in K562/ADM...
2.
Narasaki F, Oka M, Fukuda M, Nakano R, Ikeda K, Takatani H, et al.
Cancer Chemother Pharmacol
. 1997 Jan;
40(5):425-32.
PMID: 9272120
Purpose And Methods: MS-209 is a newly synthesized quinoline compound used orally to overcome human P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). The multidrug resistance-associated protein (MRP) gene is thought to play...
3.
Assessment of right ventricular contractile state with the conductance catheter technique in the pig
Dickstein M, Yano O, SPOTNITZ H, Burkhoff D
Cardiovasc Res
. 1995 Jun;
29(6):820-6.
PMID: 7656285
Objective: Since the conductance catheter method has facilitated evaluation of left ventricular contractile state in both laboratory and clinical studies, the aim of this study was to determine whether the...
4.
Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, et al.
Cancer Chemother Pharmacol
. 1995 Jan;
35(4):271-7.
PMID: 7828268
MS-209, a novel quinoline derivative, was examined for its reversing effect on multidrug-resistant tumor cells. MS-209 at 1-10 microM completely reversed resistance against vincristine (VCR) in vitro in multidrug-resistant variants...
5.
Baba M, Nakanishi O, Sato W, Saito A, Miyama Y, Yano O, et al.
Cancer Chemother Pharmacol
. 1995 Jan;
36(5):361-7.
PMID: 7634376
MS-209 is a novel quinoline compound which can overcome multidrug resistance (MDR) both in vitro and in vivo, while having a low level of side effects, and is now being...
6.
Takeda T, Nakamura T, Takashima S, Yano O, Ogihara Y
Chem Pharm Bull (Tokyo)
. 1993 Dec;
41(12):2132-7.
PMID: 8118907
Two novel triterpenoidal saponins, called calliandra saponins A and E, were isolated from the branches of Calliandra anomala (Kunth) Macbr. On the basis of the chemical and physiocochemical evidence, their...
7.
Kuramoto E, Yano O, Kimura Y, Baba M, Makino T, Yamamoto S, et al.
Jpn J Cancer Res
. 1992 Nov;
83(11):1128-31.
PMID: 1483927
Based on the previous finding that certain 30-mer single-stranded oligodeoxyribonucleotides (oligonucleotides) having particular 6-mer palindromic sequences could induce interferon-alpha and -gamma, and enhance natural killer activity, the present study was...
8.
Kuramoto E, Watanabe N, Iwata D, Yano O, Shimada S, Tokunaga T
Int J Immunopharmacol
. 1992 Jul;
14(5):773-82.
PMID: 1380950
MY-1, which consists of DNA and RNA extracted and purified from Mycobacterium bovis strain BCG, causes the regression of various experimental syngeneic tumors when injected intratumorally. In order to identify...
9.
Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T
J Immunol
. 1992 Jun;
148(12):4072-6.
PMID: 1376349
Thirty-mer single-stranded oligonucleotides, with a sequence chosen from the known cDNA encoding the 64-kDa protein named Ag A or the MPB-70 protein of Mycobacterium bovis BCG and the human cellular...
10.
Murakami T, Yano O, Takahashi H, AKIYA S, Higashi K
Nippon Ganka Gakkai Zasshi
. 1992 Jun;
96(6):737-41.
PMID: 1626475
We examined the effects of cadmium on the mRNA levels of several genes in cultured retinoblastoma (Y79) cells. After Y79 cells were treated with 15 microM CdCl2, RNA was extracted...